Soriot should explain the curious case of AstraZeneca’s non-deal
AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders AstraZeneca falls to third-largest UK company amid US merger talks Hold the heartburn pills. It seems AstraZeneca is no longer contemplating a takeover of US rival Bristol Myers Squibb (BMS) to create a $400bn (£300bn) pharmaceutical colossus . On Monday, the UK…
We haven't written up this one. Guardian Business has the full story — the link below goes straight to it.
